地方生物医药产业专项政策对创新支持的评价——以上海6部政策为例

Evaluation of Local Biopharmaceutical Industry Specific Policies on Innovation Support—Case Studies of 6 Specific Policies in Shanghai

生物医药产业发展关乎居民生命健康,生物医药创新能力是制约产业发展的关键所在。在构建PMC指数模型的基础上,对上海近十年发布的6部典型生物医药产业专项政策对区域产业创新支持程度展开量化评价,得出6部政策的PMC指数、PMC曲面图和二级指标分值箱形图。结果发现,上海生物医药产业专项政策对产业创新的支持上,2部政策表现完美、3部优秀,1部为可接受,主要聚焦在创新领域、创新主体、政策功能、保障手段上,但同时存在缺少制度规范、较少涉及企业间协同创新和国际合作、激励手段不全面以及缺少具体实施步骤等问题。在此基础上,本文为改进上海生物医药专项政策对产业创新的支持提供了相关对策与建议。

The development of biopharmaceutical industry is related to the life and health of residents, and the innovation capability of biopharmaceuticals is the key to restrict the development of the industry. Based on the construction of the PMC index model, the quantitative evaluation of the degree of support for regional industrial innovation by six typical biopharmaceutical industry-specific policies issued in Shanghai in the past ten years was conducted, and the PMC index, PMC surface plot and box plot of secondary index scores of the six policies were obtained. It is found that two policies are perfect, three are excellent, and one is acceptable in supporting industrial innovation, mainly focusing on innovation fields, innovation subjects, policy functions, and guarantee means, but there are also problems such as lack of institutional regulation, less involvement in collaborative innovation and international cooperation among enterprises, incomplete incentive means, and lack of specific implementation steps. On this basis, this paper provides countermeasures and suggestions to improve the support of Shanghai biomedical special policies for industrial innovation.